Marinus Pharmaceuticals (NASDAQ:MRNS) Earns Outperform Rating from Analysts at Cowen

Analysts at Cowen assumed coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report issued on Wednesday, The Fly reports. The brokerage set an “outperform” rating on the biopharmaceutical company’s stock.

Other research analysts have also recently issued reports about the stock. LADENBURG THALM/SH SH restated a “buy” rating and issued a $5.00 price objective on shares of Marinus Pharmaceuticals in a research report on Wednesday, April 1st. BidaskClub upgraded shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, May 28th. Cantor Fitzgerald reduced their price target on shares of Marinus Pharmaceuticals from $7.00 to $6.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 5th. Craig Hallum began coverage on shares of Marinus Pharmaceuticals in a research report on Thursday, April 9th. They set a “buy” rating and a $4.50 price target on the stock. Finally, Zacks Investment Research cut shares of Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, March 20th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. Marinus Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $4.39.

MRNS stock opened at $2.54 on Wednesday. The company’s 50 day moving average is $2.64 and its 200 day moving average is $2.21. The stock has a market cap of $217.70 million, a price-to-earnings ratio of -2.35 and a beta of 2.15. Marinus Pharmaceuticals has a 1-year low of $0.77 and a 1-year high of $4.83.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings data on Monday, May 4th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.16). Equities analysts anticipate that Marinus Pharmaceuticals will post -0.78 earnings per share for the current fiscal year.

Large investors have recently added to or reduced their stakes in the company. Asymmetry Capital Management L.P. purchased a new stake in shares of Marinus Pharmaceuticals during the fourth quarter valued at approximately $766,000. Goldman Sachs Group Inc. boosted its stake in shares of Marinus Pharmaceuticals by 14.8% during the fourth quarter. Goldman Sachs Group Inc. now owns 96,366 shares of the biopharmaceutical company’s stock valued at $208,000 after purchasing an additional 12,437 shares during the period. State Street Corp boosted its stake in shares of Marinus Pharmaceuticals by 33.0% during the first quarter. State Street Corp now owns 1,217,647 shares of the biopharmaceutical company’s stock valued at $2,472,000 after purchasing an additional 301,788 shares during the period. Oxford Asset Management LLP purchased a new stake in shares of Marinus Pharmaceuticals during the fourth quarter valued at approximately $398,000. Finally, Alyeska Investment Group L.P. boosted its stake in shares of Marinus Pharmaceuticals by 99.4% during the fourth quarter. Alyeska Investment Group L.P. now owns 2,202,012 shares of the biopharmaceutical company’s stock valued at $4,756,000 after purchasing an additional 1,097,461 shares during the period. 81.89% of the stock is owned by hedge funds and other institutional investors.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.

Featured Story: What is Blockchain?

The Fly

Analyst Recommendations for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply